Catherine Lemorton is a French pharmacist and politician. She was a member of the National Assembly of France, representing Haute-Garonne's 1st constituency,^[1] based in Toulouse, as a member of the Socialist party from 2007 to 2017. She won the 2007 election, defeating Jean-Luc Moudenc who was mayor of Toulouse at the time.

You can help expand this article with text translated from the corresponding article in French. (February 2017) Click [show] for important translation instructions. Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia. Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article. You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing French Wikipedia article at [[:fr:Catherine Lemorton]]; see its history for attribution. You may also add the template {{Translated|fr|Catherine Lemorton}} to the talk page. For more guidance, see Wikipedia:Translation.

Quick Facts députée, Assembly Member for Haute-Garonne's 1st constituency, National Assembly of France ...

députée Catherine Lemorton
Catherine Lemorton at a rallye in Toulouse
Assembly Member for Haute-Garonne's 1st constituency, National Assembly of France
In office 17 June 2007 – 2017
Preceded by	Bernadette Païx
Succeeded by	Pierre Cabaré
Personal details
Born	(1961-06-20) 20 June 1961 (age 62) Troyes, Aube
Political party	Socialist Party (France)

Close

Catherine Lemorton is known for her report (la prescription, la consommation et la fiscalité des médicaments)^[2][3] on pharmaceutical drugs, regarded as taking part in a fight against the lobbies of the pharmaceutical industry^[4] and the conflicts of interest in medicament's policies.